"The completion of this acquisition marks a pivotal step in Amneal's strategy to become America's #1 Affordable Medicines company," said Chirag Patel at closing. "With this acquisition, we have created an integrated biosimilars business that can launch multiple biosimilars each year and extends our growth profile into the next decade." At signing, Chirag Patel said the deal makes Amneal "a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines," while Chintu Patel said combining "Kashiv's deep R&D and manufacturing capabilities with our commercial strength" creates a platform to deliver "a strong and consistent cadence of biosimilar launches." Kashiv's CEO, Dr. Sandeep Athalye, called it an opportunity to combine "highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market," noting the deal builds on a collaboration of more than ten years between the companies. Amneal said the acquisition provides access to a market facing more than $300 billion of projected global biologics loss-of-exclusivity over the next decade and that it expects more than 12 commercial biosimilars by 2030 with over 20 more in the pipeline.
Under the terms of the Purchase Agreement, Amneal paid Kashiv's sellers $375 million in cash (subject to customary adjustments for cash, interim operating funding, indebtedness, transaction expenses and working capital) plus 28,942,098 shares of Class A common stock (originally 28,942,108 shares before a fractional-share adjustment), which the companies valued at signing at approximately $375 million, for combined upfront consideration of roughly $750 million. Sellers are also eligible for up to an additional $350 million in contingent payments tied to the achievement of U.S. regulatory milestones for up to six designated Kashiv product candidates, plus contingent royalty payments over a 12-year period following closing equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified hurdle amounts. A portion of the cash consideration was funded through a new $350 million incremental term loan provided by Bank of America, N.A. under Amendment No. 4 to Amneal LLC's existing Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as administrative agent.
Goldman Sachs & Co. LLC, financial advisor to the Independent Committee, rendered a fairness opinion dated April 21, 2026 covering the cash, stock, milestone and royalty consideration. In its discounted cash flow analysis, using discount rates of 11.0% to 13.0% and perpetuity growth rates of 0.0% to 1.5% (implying terminal-year EBITDA exit multiples of 5.6x to 7.8x), Goldman Sachs derived an illustrative intrinsic enterprise value for Kashiv of between $1.6 billion and $2.1 billion excluding synergies, and between $1.9 billion and $2.3 billion including Amneal's estimated cost synergies. Separately, Goldman Sachs calculated a risk-adjusted net present value of the full consideration package, finding the $350 million of contingent milestone payments (probability-weighted at 20% to 93% depending on product, discounted at an estimated 12.0% weighted average cost of capital) had a present value of approximately $125 million as of December 31, 2025.
Amneal disclosed that the transaction is "highly synergistic," with $400 million to $500 million in expected financial benefits through elimination of upcoming milestone and royalty obligations through 2030 and incremental tax and structural benefits over time, and said it expects minimal impact to its leverage profile with a path to deleveraging below 3x net leverage by 2028. The proxy statement's negotiation history shows the deal terms were substantially reduced from Kashiv's initial, non-binding June 2025 proposal, which had sought $900 million of upfront consideration ($250 million cash and $500 million stock, with Kashiv's existing term loan not deducted from the purchase price), up to $1.125 billion in success-based milestones, and a 10-year, 7.5%-of-net-sales royalty on Kashiv's first seven pipeline programs.
On the Independent Committee side, Goldman Sachs & Co. LLC served as financial advisor and Richards, Layton & Finger, P.A. and Blue Raven LLP served as outside legal counsel; The Boston Consulting Group, Inc. and InterPharmaLink AG were also engaged as industry consultants during the Committee's review. Simpson Thacher & Bartlett LLP served as legal counsel to Amneal, with KPMG US serving as Amneal's outside tax, finance and accounting advisor. On the Kashiv/seller side, J.P. Morgan Securities LLC served as financial advisor, Holland & Knight LLP served as legal counsel, and Dhinal Shah Associates served as an India-based advisor. Ernst & Young LLP audited Amneal's financial statements and Grant Thornton LLP audited Kashiv's financial statements. Innisfree M&A Incorporated acted as Amneal's proxy solicitor for the special stockholder meeting.
At a July 31, 2026 special meeting, Amneal stockholders approved both the Transaction Proposal and the Stock Issuance Proposal. Of 319,331,346 shares outstanding, 288,567,159 were present or represented by proxy, including 138,987,985 shares held by disinterested stockholders; the Transaction Proposal (requiring majority approval of disinterested stockholders under DGCL Section 144 safe-harbor standards) passed with 138,265,079 votes for, 655,759 against and 67,147 abstentions, and the Stock Issuance Proposal passed with 286,714,072 votes for, 1,791,016 against and 62,071 abstentions. The agreement was not subject to any financing condition, and the parties had set an outside date of November 17, 2026 (automatically extendable to January 12, 2027 if only certain regulatory conditions remained outstanding), though the deal closed well ahead of that date.
As required by the agreement, Amneal also issued the stock consideration in an unregistered placement under Section 4(a)(2) of the Securities Act and has agreed to file a Form S-3 resale registration statement for those shares. Amneal stated it intends to file Kashiv's historical and pro forma financial statements required under Item 9.01 by amendment within 71 days of the closing report; those statements were not yet available as of the closing 8-K and so detailed combined/pro forma income statement or balance sheet figures are not yet disclosed.